Finanzen von AVITA Medical Inc (RCEL)RCELAVITA Medical Inc

Evaluating the bottom line, AVITA Medical Inc maintains a gross margin of 82.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -31.29%, while the net margin is -35.31%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively RCEL converts its operational activities into shareholder value.

In the context of the broader market, RCEL competes directly with industry leaders such as YDES and NPCE. With a market capitalization of $476.89M, it holds a leading position in the sector. When comparing efficiency, RCEL's gross margin of 82.17% stands against YDES's 30.69% and NPCE's 82.83%. Such benchmarking helps identify whether AVITA Medical Inc is trading at a premium or discount relative to its financial performance.

AVITA Medical has demonstrated revenue growth, reporting approximately $19.3 million in Q1 2026, a 4% year-over-year increase. However, the gross margin has declined to 81.7% from 84.7% in the prior year, which could impact profitability moving forward.